Cited by 224Liver Disease Diagnosis and TreatmentFatty Acid Research and HealthAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

Open access

Argo, Curtis K., Patrie, James T., Lackner, Carolin, Henry, Thomas D., de Lange, Eduard E., Weltman, Arthur L., Shah, Neeral L., Al-Osaimi, Abdullah M., Pramoonjago, Patcharin, Jayakumar, Saumya, Binder, Lukas P., Simmons-Egolf, Winsor D., Burks, Sandra G., Bao, Yongde, Taylor, Ann Gill, Rodriguez, Jessica, Caldwell, Stephen H.·2015·Journal of Hepatology

DOI 10.1016/j.jhep.2014.08.036PMC PMC4272639

Open this paper in CoChat — free account

Abstract

Background & aims This study's aim was to assess the histological and metabolic effects of n-3 polyunsaturated fatty acids (PUFAs) vs. placebo while adjusting for the impact of age and weight change in NASH patients. (ClinicalTrials.gov: NCT00681408).Methods Forty-one subjects with non-cirrhotic NASH were enrolled, and 34 completed the study. 17 received n-3 fish oil 3000 mg/day and 17 received placebo daily for 1 year with typical counselling on caloric intake and physical activity for all subjects.Results N-3- and placebo-treated groups showed no significant difference for the primary end point of NASH activity score (NAS) reduction ⩾ 2 points without fibrosis progression after adjustment for known covariates (n-3, 4/17 (23.5%); placebo, 3/17, (17.6%), p = 0.99). Among subjects with increased or stable weight, n-3 subjects showed a larger decrease in liver fat content by MRI than placebo-treated subjects (p = 0.014 for 2nd quartile, p = 0.003 for 3rd quartile of weight change). N-3 treatment showed significant fat reduction on the paired analysis of image-assisted fat morphometry regardless of weight loss or gain. Exercise capacity remained markedly reduced in all subjects. No independent effects on markers of hepatocyte injury or insulin sensitivity indices were observed.Conclusion N-3 PUFAs at 3000 mg/day for one year did not lead to an improvement in the primary outcome of histological activity in NASH patients (⩾ 2 point NAS reduction). N-3 led to reduced liver fat by multiple measures. Other metabolic effects were not seen, although no detrimental effects were apparent. Whether longer duration, higher dose, or different composition of n-3 therapy would lead to additional benefits is uncertain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2014.08.036

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Compendium of physical activities: an update of activity codes and MET intensities
AINSWORTH, B. E., HASKELL, W. L., WHITT, M. C., IRWIN, M. L., SWARTZ, A. M., STRATH, S. J., O???BRIEN, W. L., BASSETT, D. R., SCHMITZ, K. H., EMPLAINCOURT, P. O., et al. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200009001-00009 · Cited by 8,497
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,112
The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells
Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200501 · Cited by 1,911
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338

Flagged first, then by citations

Show all 37 references

1 of the 37 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Kleiner, 2008, Creation of a continuous visual scale of ballooned hepatocytes in non-alcoholic fatty liver disease, Hepatology, 48, 815A

Sorted by citations

Items 101–200 of 224

Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity
Sistilli, G., Kalendová, V., Čajka, T., Irodenko, I., Bardová, K., Oseeva, M., Žáček, P., Kroupova, P., Horakova, O., Lackner, K., et al. (2021) · Nutrients · doi:10.3390/nu13020437 · Cited by 41
DHA supplementation prevent the progression of NASH via GPR120 signaling
Nakamoto, K., Shimada, K., Harada, S., Morimoto, Y. M., Hirasawa, A., & Tokuyama, S. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.11.046 · Cited by 38
The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells
Enguita‐Germán, M., Razquin, N., Pamplona, R., Quiroga, J. A., Prìeto, J., & Fortes, P. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1243-0 · Cited by 39
Non-pharmacological management options for MAFLD: a practical guide
Stefano, J. T., Duarte, S. M. B., Altikes, R. G., & de Oliveira, C. P. M. S. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231160394 · Cited by 42
Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long‐chain n‐3 PUFA
Delarue, J., & Lallès, J. P. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500346 · Cited by 37
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis
Essa, M., Sabry, A., Abdelsameea, E., Tharwa, E., & Salama, M. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001250 · Cited by 37
The Mexican consensus on nonalcoholic fatty liver disease
Bernal-Reyes, R., Castro‐Narro, G., Malé-Velázquez, R., Carmona-Sánchez, R., González-Huezo, M. S., García-Juárez, I., Chávez-Tapia, N. C., Aguilar-Salinas, C., Aiza-Haddad, I., Ballesteros-Amozurrutia, M. A., et al. (2019) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2019.02.003 · Cited by 35
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
Yan, M., Man, S., Ma, L., & Gao, W. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155264 · Cited by 35
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 36
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease
Byrne, C. D., & Targher, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.11.016 · Cited by 33
Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans
Kelley, N. S. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2016.0051 · Cited by 32
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis
Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32
Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Hung, C. K., & Bodenheimer, H. C. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.012 · Cited by 30
Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Chinese Medicinal Herbs Targeting the Gut–Liver Axis and Adipose Tissue–Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science
Zhang, S., Wong, Y.-T., Tang, K.-Y., Kwan, H. Y., & Su, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572729 · Cited by 28
A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model
Sangineto, M., Bukke, V. N., Bellanti, F., Tamborra, R., Moola, A., Duda, L., Villani, R., Romano, A. D., & Serviddio, G. (2021) · Nutrients · doi:10.3390/nu13020652 · Cited by 28
Ketone Body Therapy Protects From Lipotoxicity and Acute Liver Failure Upon Pparα Deficiency
Pawlak, M., Baugé, E., Lalloyer, F., Lefèbvre, P., & Staels, B. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1383 · Cited by 30
Treatment options for nonalcoholic steatohepatitis - a safety evaluation
Issa, D., Wattacheril, J. J., & Sanyal, A. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343299 · Cited by 28
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 27
Early to Phase II drugs currently under investigation for the treatment of liver fibrosis
Hauff, P., Gottwald, U., & Ocker, M. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.997874 · Cited by 27
Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials
Abdallah, M., Brown, L., Provenza, J., Tariq, R., Gowda, S. N., & Singal, A. K. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100738 · Cited by 26
Effects of calorie restriction with n-3 long-chain polyunsaturated fatty acids on metabolic syndrome severity in obese subjects: A randomize-controlled trial
Lee, H.-C., Cheng, W.-Y., Hsu, Y.-H., Su, H.-Y., Huang, B. E. T.-G., Lin, Y., Chan, W. P., Su, C., & Huang, S. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.01.040 · Cited by 26
Gamma‐Tocotrienol Attenuates the Hepatic Inflammation and Fibrosis by Suppressing Endoplasmic Reticulum Stress in Mice
Kim, Y., Natarajan, S. K., & Chung, S. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800519 · Cited by 25
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 29
Omega‐3 phospholipids and obesity‐associated NAFLD: Potential mechanisms and therapeutic perspectives
Mitrovic, M., Sistilli, G., Horakova, O., & Rossmeisl, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13650 · Cited by 25
Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
Zuo, Q., Park, N. H., Lee, J. K., Casiano, A. S., & Madak‐Erdogan, Z. (2023) · Steroids · doi:10.1016/j.steroids.2023.109330 · Cited by 23
IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Duarte, S. M. B., Stefano, J. T., Vanni, D. S., Carrilho, F. J., & de Oliveira, C. P. M. S. (2019) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201900000-67 · Cited by 24
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
Sridharan, K., Sivaramakrishnan, G., Sequeira, R. P., & Elamin, A. (2018) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-135967 · Cited by 22
Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
Perdomo, C. M., Garcı́a-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 21
N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune–Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses
Vielma, F. H., Valenzuela, R., Videla, L. A., & Zúñiga‐Hernández, J. (2021) · Nutrients · doi:10.3390/nu13103384 · Cited by 21
The potential role of statins in treating liver disease
Imprialos, K. P., Stavropoulos, K., Doumas, M. N., Skalkou, A., Zografou, I., & Athyros, V. G. (2018) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2018.1439379 · Cited by 21
Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches
Cogorno, L., Formisano, E., Vignati, A., Prigione, A., Tramacere, A., Borgarelli, C., Sukkar, S. G., & Pisciotta, L. (2023) · Liver Research · doi:10.1016/j.livres.2023.08.005 · Cited by 19
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Sokal-Dembowska, A., Jarmakiewicz-Czaja, S., Ferenc, K., & Filip, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105238 · Cited by 19
Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
Zhong, J., Cai, Z., Zhu, G., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16348 · Cited by 18
Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials
Kim, S. J., Cho, S. H., & Yun, J. M. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.05.013 · Cited by 18
Biosynthetic deficiency of docosahexaenoic acid causes nonalcoholic fatty liver disease and ferroptosis-mediated hepatocyte injury
Li, X., Liu, C., Zhang, R., Li, Y., Ye, D., Wang, H., He, M., & Sun, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107405 · Cited by 19
Severe nonalcoholic steatohepatitis and type 2 diabetes: liver histology after weight loss therapy in a randomized clinical trial
Oshakbayev, K., Bimbetov, B., Manekenova, K., Bedelbayeva, G., Mustafin, K., & Dukenbayeva, B. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1547696 · Cited by 18
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
Cernea, S., & Onișor, D. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.286 · Cited by 18
Effect of portulaca oleracea (purslane) extract on inflammatory factors in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial
Damavandi, R. D., Shidfar, F., Najafi, M., Janani, L., Masoodi, M., Heshmati, J., & Ziaei, S. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105465 · Cited by 17
Natural compounds proposed for the management of non-alcoholic fatty liver disease
Merenda, T., Juszczak, F., Ferier, E., Duez, P., Patris, S., Declèves, A., & Nachtergael, A. (2024) · Natural Products and Bioprospecting · doi:10.1007/s13659-024-00445-z · Cited by 18
A randomized controlled trial comparing effects of a low-energy diet with n-3 polyunsaturated fatty acid supplementation in patients with non-alcoholic fatty liver disease
Shojasaadat, F., Ayremlou, P., Hashemi, A., Mehdizadeh, A., & Zarrin, R. (2019) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_282_18 · Cited by 16
Nonalcoholic fatty liver disease: implications for cardiovascular risk
Dinani, A. M., & Sanyal, A. J. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000126 · Cited by 16
Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes
Orsu, P., & Bhuvaneswari, M. (2020) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_86_20 · Cited by 17
Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease
Sandby, K., Geiker, N. R. W., Dalamaga, Μ., Grønbæk, H., & Magkos, F. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00430-4 · Cited by 16
Relationship Between Fish Oil Use and Incidence of Primary Liver Cancer: Findings From a Population-Based Prospective Cohort Study
Jiang, W., Li, F.-R., Yang, H.-H., Chen, G.-C., & Hua, Y.-F. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.771984 · Cited by 16
Effective Food Ingredients for Fatty Liver: Soy Protein β-Conglycinin and Fish Oil
Yamazaki, T., Li, D., & Ikaga, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124107 · Cited by 16
Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
Huang, J., Chang, T., Yeh, M., Shen, F., Tai, C., Chen, J., Huang, Y., Hsu, C., Cheng, P., Lin, C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000571 · Cited by 15
In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children
Nobili, V., Alisi, A., Liu, Z., Liang, T., Crudele, A., Raponi, M., Lin, J., Chalasani, N., & Liu, W. (2018) · Pediatric Research · doi:10.1038/s41390-018-0132-7 · Cited by 15
S2k-Leitlinie Klinische Ernährung in der Hepatologie
Plauth, M., Bechmann, L. P., Grajecki, D., Gundling, F., Kramer, L., Kremer, A. E., Rau, M., Schneider, A., Tacke, F., & van Thiel, I. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2338-1144 · Cited by 14
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Wang, Y., He, Y., Sun, W., Yu, H., Tao, W., Yu, X., Jia, D., Liu, Y., Pandol, S. J., & Li, L. (2024) · Drugs · doi:10.1007/s40265-024-02015-6 · Cited by 15
How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease
Ismaiel, A., & Dumitrascu, D. L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001174 · Cited by 14
Endogenously increased n-3 PUFA levels in fat-1 transgenic mice do not protect from non-alcoholic steatohepatitis
Liebig, M., Dannenberger, D., Vollmar, B., & Abshagen, K. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.04.03 · Cited by 13
Differential Effects of Dietary White Meat and Red Meat on NAFLD Progression by Modulating Gut Microbiota and Metabolites in Rats
Li, J., Li, Y., Feng, S., He, K., Guo, L., Chen, W., Wang, M., Zhong, L., Wu, C., Peng, X., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6908934 · Cited by 12
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Association of fish and meat consumption with non-alcoholic fatty liver disease: Guangzhou Biobank Cohort Study
Wang, R. Z., Zhang, W. S., Jiang, C. Q., Zhu, F., Jin, Y. L., & Xu, L. (2023) · BMC Public Health · doi:10.1186/s12889-023-17398-6 · Cited by 12
Tratamiento actual de la enfermedad por hígado graso no alcohólico
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2017.10.003 · Cited by 11
Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop
Peters, H. P. F., Schrauwen, P., Verhoef, P., Byrne, C. D., Mela, D. J., Pfeiffer, A. F. H., Risérus, U., Rosendaal, F. R., & Schrauwen‐Hinderling, V. B. (2017) · Journal of Nutritional Science · doi:10.1017/jns.2017.13 · Cited by 11
Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
Zhou, L., Sun, D., & Bai, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1524830 · Cited by 10
Fatty acid composition but not quantity is an important indicator of non-alcoholic fatty liver disease: a systematic review
Das, A., Tang, Y. L. M., Althumiri, N. A., García-Larsen, V., Schattenberg, J. M., & Alqahtani, S. A. (2023) · European Journal of Clinical Nutrition · doi:10.1038/s41430-023-01335-2 · Cited by 10
Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease
Marinho, P., Vieira, A. B., Pereira, P. G., Rabelo, K., Ciambarella, B. T., Nascimento, A. L. R., Cortez, E. A. C., Moura, A. S., Guimarães, F. V., Martins, M. A., et al. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/4956079 · Cited by 9
Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness
Dahmus, J., Hummer, B. L., Rivas, G., Schmitz, K. H., Caldwell, S. H., Argo, C. K., Schreibman, I. R., & Stine, J. G. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07809-w · Cited by 9
Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand?
Caldwell, S. H., & Argo, C. K. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3540-0 · Cited by 9
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
Boccatonda, A., D’Ardes, D., Moronti, V., Santilli, J., Cipollone, A., Lessiani, G., Gregorio, N. D., Serra, C., Piscaglia, F., Ferri, C., et al. (2024) · Medicina · doi:10.3390/medicina60111781 · Cited by 8
Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis
Vuille‐Lessard, É., Lange, N. F., Riebensahm, C., Dufour, J., & Berzigotti, A. (2021) · Current Hepatology Reports · doi:10.1007/s11901-021-00563-z · Cited by 9
Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta‐Analysis
Shi, R., Chai, K., Wang, H., Zhou, J., Yang, S., Li, J., Qiao, C., Sheng, X., Zhang, X., & Wu, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70002 · Cited by 9
Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial
Barroso, L. N., Salarini, J. S., Leite, N. C., Villela‐Nogueira, C. A., Dávalos, A., Carmo, M. D. G. T., & Peres, W. A. F. (2023) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2023.06.027 · Cited by 8
Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice
Perdomo, C. M., D’Ingianna, P., Escalada, J., Petta, S., Romero‐Gómez, M., & Ampuero, J. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15510 · Cited by 8
Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids
Jeyakumar, S. M., & Vajreswari, A. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i31.9333 · Cited by 8
Current treatment for non-alcoholic fatty liver disease
Moctezuma‐Velázquez, C. (2018) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2018.05.014 · Cited by 8
Nonalcoholic Fatty Liver Disease
Argo, C. K., Henry, Z. H., & Caldwell, S. H. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch32 · Cited by 7
Current Treatment Options, Including Diet, Exercise, and Medications
Noureddin, M., & Abdelmalek, M. F. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.008 · Cited by 6
Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD
Sabinari, I. W., Horakova, O., Čajka, T., Kleinova, V., Wieckowski, M. R., & Rossmeisl, M. (2024) · Physiological Research · doi:10.33549/physiolres.935396 · Cited by 7
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience
Al‐Judaibi, B., Thomas, B., Wong, P. Y. N., Benmassaoud, A., Chen, J.-H., Dokus, M. K., Hussaini, T., Bilodeau, M., Burak, K. W., Marotta, P., et al. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0011.7388 · Cited by 6
Macronutrient Modulation in Metabolic Dysfunction-Associated Steatotic Liver Disease—the Molecular Role of Fatty Acids compared with Sugars in Human Metabolism and Disease Progression
Mullin, S. M., Kelly, A. J., Chathail, M. B. N., Norris, S., Shannon, C. E., & Roche, H. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100375 · Cited by 10
Two decades of FFAR4 biology: From nutrient sensing to therapeutic targeting
Kong, Y., Oh, D., & Zhu, S. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116586 · Cited by 5
Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Sogbe, M., Hummer, B. L., Stine, J. G., Lizaola‐Mayo, B., Forman, D. E., Vargas, H. E., & Duarte‐Rojo, A. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08893-4 · Cited by 4
Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
Perva, I. T., Simina, I.-E., Bende, R., Motofelea, A. C., Chiriță-Emandi, A., Andreescu, N. I., Sima, A. C., Vlad, A., Sporea, I., Zimbru, C. G., et al. (2024) · Medicina · doi:10.3390/medicina60081366 · Cited by 4
High levels of serum dihomo-γ-linolenic acid are associated with non-alcoholic fatty liver disease in type 2 diabetic patients
Mochizuki, K., Higa, M., Ikehara, K., Ichijo, T., & Hirose, T. (2024) · Diabetology International · doi:10.1007/s13340-024-00760-3 · Cited by 4
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease
Chew, N., Muthiah, M. D., & Sanyal, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00003-6 · Cited by 4
Dietary Management of Nonalcoholic Fatty Liver Disease (NAFLD) by n-3 Polyunsaturated Fatty Acid (PUFA) Supplementation
Jeyakumar, S., & Vajreswari, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00030-6 · Cited by 4
Immunonutrition: Another Player on the MASLD Field
López-Méndez, I., Uribe, M., & Juárez-Hernández, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188928 · Cited by 4
A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Nakamoto, K., Obata, T., Hirasawa, A., Kim, K. I., Kim, S. R., & Tokuyama, S. (2016) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.15-00264-4 · Cited by 3
The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels.
Check, J. H., Brasile, D., Jk, C., Amui, J., & Wilson, C. (2009) · PubMed · Cited by 3
Nonalcoholic liver disease: review with a focus on risks of progression
Teplyuk, D. A., Semenistaya, M. C., Sorokoletov, S. M., Лазебник, Л. Б., & Pavlov, C. S. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-192-8-167-174 · Cited by 3
Extracellular Vesicles and Fatty Liver
Lu, X., Song, M., & Gao, N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-1443-2_9 · Cited by 3
Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study
Takeda, Y., Furuhashi, M., Sakuma, I., Hiramitsu, S., Okada, M., Ueda, S., Kumashiro, N., & Sakurai, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1549687 · Cited by 3
Effect of mediterranean diet on non-alcoholic fatty liver disease (NAFLD)
Walczak, P., Walczak, K., Zdun, S., Nemeczek, S., MERKISZ, K., Grzybowski, J., Marciniak, A., Grzywna, N., JASKUŁA, K., & ORŁOWSKI, W. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.03.008 · Cited by 3
Qualitative Properties of Circulating Fatty Acids Are Associated With MASLD : A Cross‐Sectional Study From the NHANES Database
Ciardullo, S., Vergani, M., Rizzo, M., Oltolini, A., Bongo, A., Muraca, E., & Perseghin, G. (2025) · Liver International · doi:10.1111/liv.70441 · Cited by 2
“NASH-Worldwide the Commonest Aetiology of Liver Cirrhosis”- a Review Article
Jannat, S. N. E., Islam, M. M. S. U., Haque, M. M., Imam, I., & Ahmed, D. S. (2023) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v2i2.69844 · Cited by 2
How Much Fat Does One Need to Eat to Get a Fatty Liver? A Dietary View of NAFLD
Sasdelli, A. S., Barbanti, F. A., & Marchesini, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-30361-1_8 · Cited by 2
Pathogenetic substantiation of approaches to the treatment of non-alcoholic fatty liver disease.
Bogomolov, P., Мациевич, М. В., Kokina, K. Y., Mayorov, A. Y., & Mishina, E. Е. (2018) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-12-1077-1085 · Cited by 2
Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration
Palmieri, B., Corazzari, V., BRASILE, D. G. P., Sangiovanni, V., & VADALÀ, M. (2021) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.20.02738-5 · Cited by 2
Nonalcoholic Fatty Liver Disease and Obesity
De, A., & Duseja, A. K. (2021) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1430 · Cited by 2
What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis
Koutoukidis, D. A., Morris, E. M., Henry, J. A., Shammoon, Y., Zimmerman, M., Michalopoulou, M., Jebb, S. A., & Aveyard, P. N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250385 · Cited by 2
The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis
Sharma, S. K., Sharma, A., Gupta, P., Arora, D., Deswal, G., Grewal, A. S., & Sharma, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x360903250211101856 · Cited by 1
Effects of Degossypolized Cottonseed Protein on the Laying Performance, Egg Quality, Blood Indexes, Gossypol Residue, Liver and Uterine Histopathological Changes, and Intestinal Health of Laying Hens
Li, R., Luo, X., Bai, S., Ding, X., Wang, J., Zeng, Q., Xuan, Y., Li, S., Qi, S., Bi, X., et al. (2025) · Agriculture · doi:10.3390/agriculture15141482 · Cited by 1
Association of Pro‐Inflammatory Diets With Increased Risk of Metabolic Dysfunction‐Associated Steatohepatitis: Evidence From a Prospective Cohort Study
Fathi, S., Pasdar, Y., Moradinazar, M., Iranshahi, A. M., Najafi, F., Miryan, S., Sedighi, M., Shahnazi, N., Saber, A., & Soleimani, D. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72109 · Cited by 1
Non-Alcoholic Fatty Liver Disease: Bases for Therapeutic Roles of Vitamin E and n-3 PUFA
Rodrigo, R. (2017) · Journal of Liver Research Disorders & Therapy · doi:10.15406/jlrdt.2017.03.00079 · Cited by 1

Authors: Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., Binder, L. P., Simmons-Egolf, W. D., Burks, S. G., Bao, Y., Taylor, A. G., Rodriguez, J., & Caldwell, S. H.
Affiliations: University of Virginia Health System (US)
University of Virginia (US)
Medical University of Graz (AT)
University of Calgary (CA)
Corresponding author: Argo, Curtis K.
Caldwell, Stephen H.
ORCID: Argo, Curtis K.
Patrie, James T.
Lackner, Carolin
Weltman, Arthur L.
Shah, Neeral L.
Pramoonjago, Patcharin
Jayakumar, Saumya
Binder, Lukas P.
Burks, Sandra G.
Bao, Yongde
Caldwell, Stephen H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2015-01
Volume: 62
Issue: 1
Pages: 190-197
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2014.08.036
PMC: PMC4272639
OpenAlex: W2019810874
Cited by: 224
References: 37
Citations by year: 2026: 7 · 2025: 16 · 2024: 17 · 2023: 21 · 2022: 13 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 30 · 2017: 24 · 2016: 19 · 2015: 21
FWCI: 16.41
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Virginia
National Center for Research Resources (5 M01 RR00847, M01RR000847)
National Center for Complementary and Integrative Health (R21AT002901, 5R21AT2901-2)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: omega-3 polyunsaturated fatty acids, nonalcoholic steatohepatitis, liver fat, weight change, exercise capacity, insulin sensitivity, hepatocyte injury, non-cirrhotic liver disease
MeSH terms: Adult, Aged, Biopsy, Double-Blind Method, Energy Metabolism, Female, Follow-Up Studies, Humans, Liver, Male, Middle Aged, Retrospective Studies, Fatty Acids, Omega-3, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks